Applying epidemiology-based outcomes research to clinical decision- making: A hypothetical model of biotechnology therapy in gram-negative sepsis

PharmacoEconomics

Volumn 15, Issue 4, 1999, Pages 385-393

  Wang, Edward C Y ^a,c   Grasela, Thaddeus H ^b   Walawander, Cynthia A ^b  

^a PFIZER INC   (United States)

^b Pharmaceutical Outcomes Res Inc   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BIOTECHNOLOGY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FEMALE; HEALTH SERVICE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEPSIS; TREATMENT OUTCOME;

DECISION MAKING; EPIDEMIOLOGIC METHODS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MODELS, THEORETICAL; TREATMENT OUTCOME;

EID: 0032931109     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199915040-00006     Document Type: Article

References (23)

1. 1. Pinner RW, Teutsch SM, Simonsen L, et al. Trends in infectious diseases mortality in the United States. JAMA 1996; 275: 189-93
2. 2. Ziegler EJ, Fisher Jr CJ, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991; 324: 429-36
3. 3. Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991; 226: 1097-102
4. 4. Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995; 23: 994-1006
5. 5. McCloskcy RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A. Ann Intern Med 1994; 121: 1-5
6. 6. Bernard GR. Sepsis trials: intersection of investigation, regulation, funding, and practice. Am J Respir Crit Care Med 1995; 152: 4-10
7. 7. Schulman KA, Yabroff KR, Glick H. A health services approach for the evaluation of innovative pharmaceutical and biotechnology products. Drug Inf J 1995; 29: 1405-14
8. 8. Conboy K, Welage LS, Walawander CA, et al. Sepsis syndrome and associated sequelae in patients at high risk for gram-negative sepsis. Pharmacotherapy 1995; 15: 66-77
9. 9. Chalfin DB, Holbein MEB, Fein AM, et al. Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients. JAMA 1993; 269: 249-54
10. 10. Schulman KA, Glick HA, Rubin H, et al. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. JAMA 1991; 266: 3466-71
11. 11. Weinstein MC, Fineberg HV, Elstein AS, et al. Clinical decision analysis. Philadelphia (PA): WB Saunders Company, 1980
12. 12. Brady HR, Brenner BM. Acute renal failure. In. Isselbacher K, Braunwald E, Wilson JD, et al., editors. Harrison's principles of internal medicine. New York (NY): McGraw-Hill Inc, 1994: 1265-74
13. 13. Ingram Jr RH. Adult respiratory distress syndrome. In: Isselbacher K, Braunwald E, Wilson JD, et al., editors. Harrison's principles of internal medicine. New York (NY): McGraw-Hill Inc. 1994: 1240-3
14. 14. Handin RI. Disorders of coagulation and thrombosis. In: Isselbacher K, Braunwald E, Wilson JD, et al., editors. Harrison's principles of internal medicine. New York (NY): McGraw-Hill Inc, 1994: 1804-10
15. 15. Wilkins JC, Dabrows MB. Hematologic emergencies: management of hyperleukocytic syndrome, DIC, and thrombotic thrombocytopenic purpura. Postgrad Med 1993; 93: 193-202
16. 16. Parno JR, Teres D, Lemeshow S, et al. Hospital charges and long-term survival of ICU versus non-ICU patients. Crit Care Med 1982; 10: 569-74
17. 17. Jacobs P, Noseworthy TW. National estimates of intensive care utilization and costs: Canada and the United States. Crit Care Med 1990; 18: 1282-6
18. 18. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis. New York (NY): Oxford University Press, 1994
19. 19. Hollenberg J. SMLTREE: the all-purpose decision-tree builder. Boston (MA): Pratt Medical Group, 1985
20. 20. Pauker SG, Kassirer JP. Decision analysis. N Engl J Med 1987; 316: 250-8
21. 21. HCIA Inc, Ernst and Young LLP. The DRG handbook: comparative clinical and financial standards. Baltimore (MD): HCIA Inc, 1995
22. 22. Chassin MR. Costs and outcomes of medical intensive care. Med Care 1982; 20: 165-79
23. 23. Dragsted L, Qvist J. Epidemiology of intensive care. Int J Technol Assess Health Care 1992; 8: 395-407